Charlotte Parker, Author at Oral Cancer News

The cancer-causing sex virus

Source: Forbes Author: Matthew Herper Martin Duffy, a Boston consultant and economist, thought he just had a sore throat. When it persisted for months, he went to the doctor and learned there was a tumor on his tonsils. Duffy, now 70, had none of the traditional risk factors for throat cancer. He doesn't smoke, doesn't drink and has run 40 Boston marathons. Instead, his cancer was caused by the human papilloma virus (HPV), which is sexually transmitted and a common cause of throat and mouth cancer. HPV tumors have a better prognosis than those caused by too many years of booze and cigarettes. But Duffy "is in the unlucky 20%" whose cancer comes back--despite rounds of chemotherapy and radiation that melted 20 more pounds off a lean 150-pound frame. Now the cancer has spread throughout his throat, making eating and talking difficult. "I made my living as a public speaker," he says. "Now I sound like Daffy Duck." Duffy believes he has only a few months left. "How do you tell the people you love you love them?" he asks. Nine Things You Need To Know About HPV Most strains of the HPV virus are harmless, but persistent infections with two HPV strains cause 70% of the 12,000 cases of cervical cancers diagnosed annually in the U.S. Other forms of the sexually transmitted virus can cause penile and anal cancer, and genital warts. The HPV throat cancer connection has emerged in just the last few years and is so new that [...]

Charlotte Parker2010-07-25T20:13:00-07:00July, 2010|Oral Cancer News|

Mice with toys and friends have better anti-cancer responses

Source: Medscape Blogs Author: Alok Khorana, MD As clinicians, we know that patients with excellent support systems will (in general) do better than patients without. I had personally always thought of this as being secondary to better reporting and oversight - for instance, a patient with a spouse is more likely to be brought in with a fever whereas a patient living by him/herself is more likely to try and ride it out, leading to more dangerous complications. In a fascinating animal model study published in Cell, researchers led by Cao et al at identify even more of a therapeutic benefit for having such an "enriched environment". The authors show this by placing mice with different types of cancers (melanoma, colon cancer) in two different types of environments: one, the usual laboratory housing (5 mice per cage) and the other "enriched" with "groups (18-20 mice per cage) in large cages of 1.5 m x 1.5 m x 1.0 m supplemented with running wheels, tunnels, igloos, huts, retreats, wood toys, a maze, and nesting material". The results all clearly favored having an enriched environment: "In the mice housed in enriched environment for 3 weeks prior to tumor implantation, the mean volume of the tumor was 43% smaller than those in the control housing (p < 0.05). For the 6 week groups, the tumor mass in EE mice was reduced by 77.2% p < 0.001). Notably, all mice in the control groups developed solid tumors, whereas 5% of mice with 3 weeks [...]

Charlotte Parker2010-07-25T20:12:24-07:00July, 2010|Oral Cancer News|

Head and neck cancer among lifelong never-smokers and ever-smokers: matched-pair analysis of outcomes after radiation therapy

Source: HighWire Medline Author: Am J Clin Oncol From the Departments of *Radiation Oncology and daggerOtolaryngology-Head and Neck Surgery, University of California Davis School of Medicine, Sacramento, CA. PURPOSE:: An increasing proportion of patients with head and neck cancer have no history of smoking. The purpose of this analysis was to compare the clinical outcomes between patients without a history of smoking (never-smokers) and those with a previous history of smoking (ever-smokers) treated by radiation therapy. METHODS AND MATERIALS:: Seventy patients with newly diagnosed squamous cell carcinoma of the oropharynx or oral cavity without a previous history of smoking were matched to a control ever-smoker with a positive tobacco history (>10 pack-years) based on age, gender, ethnicity, Karnofsky Performance Status, primary tumor site, disease stage, primary treatment, radiation dose, and start date. Outcome was compared using Kaplan-Meier analysis. Normal tissue effects were graded according to the Radiation Therapy Oncology Group/European Organization for the Treatment of Cancer radiation toxicity criteria. RESULTS:: With a median follow-up of 33 months, lifelong never-smokers had an increased 3-year overall survival (86% vs. 69%), disease-free survival (82% vs. 65%), and local-regional control (85% vs. 70%) compared with the ever-smoker control population (P < 0.05, for all). These differences remained statistically significant when patients treated by postoperative or definitive radiation therapy were analyzed separately. The incidence of grade 3+ complications was also significantly lower among never-smokers compared with ever-smokers (10% vs. 29%, P = 0.01). CONCLUSIONS:: Prognosis differed significantly between never-smokers and ever-smokers with head and neck [...]

Charlotte Parker2010-07-20T14:11:01-07:00July, 2010|Oral Cancer News|

Dysphagia, stricture, and pneumonia in head and neck cancer patients: does treatment modality matter?

Source: HighWire Medline Author: Ann Otol Rhinol Laryngol Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, Washington, USA. OBJECTIVES: Dysphagia-related sequelae are common after head and neck cancer treatment. Our aims were 1) to document overall and site-specific dysphagia, stricture, and pneumonia rates in a Medicare population, 2) to calculate treatment-specific rates and adjusted odds of developing these complications, and 3) to track changes in rates between 1992 and 1999. METHODS: Head and neck cancer patients between 1992 and 1999 were identified in combined Surveillance Epidemiology and End Results (SEER) registry and Medicare databases. Multivariate analyses determined odds of dysphagia, stricture, and pneumonia based on modality. RESULTS: Of 8,002 patients, 40% of experienced dysphagia, 7% stricture, and 10% pneumonia within 3 years of treatment. In adjusted analyses, patients treated with chemoradiation had more than 2.5-times-greater odds of dysphagia than did those treated with surgery alone. Combined therapy was associated with increased odds of stricture (p<0.05). The odds of pneumonia were increased in patients treated with radiation with or without chemotherapy. Temporally, the dysphagia rates increased 10% during this period (p<0.05). CONCLUSIONS: Sequelae of head and neck cancer treatment are common and differ by treatment regimen. Those treated with chemoradiation had higher odds of experiencing dysphagia and pneumonia, whereas patients treated with any combined therapy more commonly experienced stricture. These sequelae represent major sources of morbidity and mortality in this population.

Charlotte Parker2010-07-20T11:56:04-07:00July, 2010|Oral Cancer News|

Which new tobacco products are scoring?

Source: CSP Author: Mitch Morrison OAK BROOK, Ill. -- Camel Snus continues to ride a wave of loyal national support as R.J. Reynolds extends its marketing focus to oral tobacco consumption. In an exclusive CSP-UBS tobacco survey, retailers praised Camel's Snus product as well as Camel Crush, the company's customizable cigarette that contains a small blue menthol capsule within the filter. "Camel Snus—extremely aggressive and the first to market in this new and growing category," a Virginia retailer said of the smokeless, spitless product. "'Fill the Fridge' is a good concept." Added a retailer from Iowa: "Snus continues to be a growth driver. Camel did a really good job out of the chute with its initial launch and now Marlboro has gotten into the game as well." Indeed, more than half of the 50-plus respondents cited the snus segment as a strong nascent player that is slowly gaining recognition and consumer acceptance. Another winner was Marlboro, which scored well with its Marlboro 72, Marlboro Special Blend and Copenhagen Wintergreen smokeless tobacco. "Marlboro Special Blend and 72s have done exceptionally well in our area with an attractive price," an Arkansas operator said. Others receiving praise included Liggett's private-label lines, Star Scientific's Stonewall spitless, Reynold's Natural American Spirit and the broader smokeless tobacco category. "Camel is doing a great job in building awareness for the Snus category," said UBS tobacco analyst Nik Modi. "PM USA had great traction with its Marlboro Special Blend, but we wonder how the brand will respond to [...]

Charlotte Parker2010-07-14T20:16:42-07:00July, 2010|Oral Cancer News|

Congress approves bill curbing internet tobacco sales in victory for kids and taxpayers

Source: Campaign for Tobacco-Free Kids Author: Matthew L. Myers Voting 387 to 25, the U.S. House of Representatives today gave final congressional approval to the Prevent All Cigarette Trafficking (PACT) Act, legislation to curtail the growing sales of tax-evading, low-cost cigarettes and other tobacco products over the Internet and through the mail. Passage of this legislation is a milestone in the fight to keep kids from smoking and prevent tax evasion that costs state and federal taxpayers billions each year. We applaud Rep. Anthony Weiner (D-NY), the chief House sponsor, and Sen. Herb Kohl (D-WI), the Senate sponsor, for their leadership and persistence in pursuing this legislation and winning its approval. The Senate unanimously approved the bill onMarch 11. We look forward to President Obama continuing his strong leadership on tobacco control by signing the PACT Act into law. Internet sales of tobacco products are a serious and growing problem that keeps prices down and smoking levels up. Such sales make it easier and cheaper for kids to buy cigarettes, facilitate tax evasion and cost federal and state governments billions in revenue. Many vendors that sell cigarettes and smokeless tobacco products over the Internet or through other mail-order sales do not pay applicable tobacco taxes and do not have sufficient safeguards to prevent sales to children, such as effective policies to verify a purchaser's age. The PACT Act will: Require Internet sellers to pay all federal, state, local or Tribal tobacco taxes and affix tax stamps before delivery to any customer; Mandate that the [...]

Charlotte Parker2010-07-14T20:16:19-07:00July, 2010|Oral Cancer News|

Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006

Source: Ann Royal Coll Surgery Engl. 2010 Jul 7 Authors: Reddy V, Cundall-Curry D, Bridger M. Abstract: INTRODUCTION The aim of this study was to investigate whether incidence rates of tonsil and base of tongue cancer in England are increasing using data from the UK cancer registry. SUBJECTS AND METHODS Cancer registrations for oral cavity and oropharynx cancer from 1985-2006 in England were obtained from the National Cancer Information Service. Population estimates were obtained from the Office for National Statistics. Age-adjusted incidence rates and age-specific incidence rates were calculated. The sexes were considered separately as incidence rates are known to differ significantly between men and women. Linear regression was performed to establish whether there was a relationship between incidence rates and time. RESULTS There has been an increase in all oral cavity and oropharyngeal cancer in the study period. Linear regression analysis suggests that approximately 90% of the variance in age-adjusted incidence rates for men and women for tonsil, base of tongue and other oral cavity cancer is explained by the passage of time. For other oropharyngeal cancer, the variance is 62% and 46% in men and women, respectively. The estimated annual percentage change from 1985 to 2006 in age-adjusted incidence rates for tonsil and base of tongue cancer is 5.7% and 6.7% for men, and 4.3% and 6.5% for women, respectively. CONCLUSIONS This study confirms a wide-spread clinical impression that there has been an increase in age-adjusted incidence rates, between 1985 and 2006, in all oral cavity cancer in England. [...]

Charlotte Parker2010-07-12T11:23:01-07:00July, 2010|Oral Cancer News|

A tough one to chew on: smokeless tobacco and teens

Source: Medscape Today Author: Mary E. Muscari, PhD, CPNP, APRN-BC, CFNS Introduction One would think that the mere image of a bulgy cheek spewing brown, foul-smelling goo would be more than enough to turn anyone, especially appearance-conscious teens, off of using smokeless tobacco (ST). But then, these media-savvy adolescents probably have discovered snus, a smoke- and spit-free tobacco. According to a recent article in Reuters,[1] the use of ST is on the rise among US teens, reversing a downward trend in tobacco product use by adolescents. The Reuters article cites comments made by Terry Pechacek, PhD, Associate Director for Science, Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), in a report to a US Congressional Panel. Among his comments is the suggestion that ST-using Major League Baseball® (MLB) players may be influencing young men to take up the cancer-causing habit. In his report, Dr. Pechacek noted that "the recent increases in ST use by adolescent boys and young adult men and the increasing dual use of cigarettes and ST products may portend a leveling off or even a reversal in the decline in smoking, the perpetuation of nicotine dependence, and continuing high levels of tobacco-related disease and death in the country."[2] Given this grim outlook, healthcare professionals need to kick up their fight against teen tobacco use by increasing their focus on smokeless forms of tobacco. Smokeless Tobacco ST (also known as spit, plug dip, chaw, rack, spits, grizz, [...]

Charlotte Parker2010-07-10T06:34:38-07:00July, 2010|Oral Cancer News|

VELscope system honored by the WHO

Source: Dentistry IQ Author: Staff Jul 7, 2010 BURNABY, British Columbia—LED Dental has announced that the World Health Organization has recognized the VELscope enhanced oral assessment system as an innovative device that addresses global health concerns. In 2009, the WHO Department of Essential Health Technologies challenged the scientific and business communities to identify and develop innovative technologies to address global health concerns. On June 30, following months of evaluation, the organization officially recognized those innovative medical devices--either existing or under development--that address global health concerns and which are likely to be accessible, appropriate and affordable for use in low- and middle-income countries. The VELscope system was one of only eight commercialized devices so honored. “It is extremely gratifying to receive this prestigious honor,” said Peter Whitehead, founder and CEO of LED Dental and inventor of the VELscope system. “We created the VELscope system to improve the oral health of patients worldwide by helping dental practitioners discover everything from early-stage oral cancer to any number of more common oral abnormalities. This recognition from the World Health Organization is further reinforcement of what thousands of VELscope users have been telling us: that the VELscope system can help improve oral health in a very cost-effective and userfriendly manner.” Oral cancer kills one American every hour of every day. According to the SEER data base, oral cancer has a higher mortality rate than several better publicized cancers, such as cervical cancer and testicular cancer. Some oral cancers are now known to be linked to [...]

Charlotte Parker2010-07-08T13:14:47-07:00July, 2010|Oral Cancer News|

Coffee and tea intake and risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium

Source: CEBP Author: Mia Hashibe Abstract Background: Only a few studies have explored the relation between coffee and tea intake and head and neck cancers, with inconsistent results. Methods: We pooled individual-level data from nine case-control studies of head and neck cancers, including 5,139 cases and 9,028 controls. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI), adjusting for potential confounders. Results: Caffeinated coffee intake was inversely related with the risk of cancer of the oral cavity and pharynx: the ORs were 0.96 (95% CI, 0.94–0.98) for an increment of 1 cup per day and 0.61 (95% CI, 0.47–0.80) in drinkers of >4 cups per day versus nondrinkers. This latter estimate was consistent for different anatomic sites (OR, 0.46; 95% CI, 0.30–0.71 for oral cavity; OR, 0.58; 95% CI, 0.41–0.82 for oropharynx/hypopharynx; and OR, 0.61; 95% CI, 0.37–1.01 for oral cavity/pharynx not otherwise specified) and across strata of selected covariates. No association of caffeinated coffee drinking was found with laryngeal cancer (OR, 0.96; 95% CI, 0.64–1.45 in drinkers of >4 cups per day versus nondrinkers). Data on decaffeinated coffee were too sparse for detailed analysis, but indicated no increased risk. Tea intake was not associated with head and neck cancer risk (OR, 0.99; 95% CI, 0.89–1.11 for drinkers versus nondrinkers). Conclusions: This pooled analysis of case-control studies supports the hypothesis of an inverse association between caffeinated coffee drinking and risk of cancer of the oral cavity and pharynx. Impact: Given widespread use of coffee [...]

Charlotte Parker2010-07-10T06:33:58-07:00July, 2010|Oral Cancer News|

Oral Cancer News
Compiled by The Oral Cancer Foundation

About Charlotte Parker